AnteoTech has set sales conversion as its FY2027 priority after FY2026 sales revenue slipped to A$460,397, while operating expenses fell sharply and cash stood at A$11.2 million. The battery materials and life sciences company says customer evaluations and partnership discussions are building, but most opportunities remain short of recurring commercial revenue.
- FY2026 sales revenue of A$460,397, down from A$467,589
- Total revenue fell to A$3.13 million
- Operating expenses reduced to A$6.86 million, excluding non-cash items
- Cash balance stood at A$11.2 million at 30 June 2026
- FY2027 focus shifts to converting evaluations into sales
Sales Pipeline Must Now Produce Revenue
AnteoTech Ltd (ASX:ADO) is entering FY2027 with a clear commercial test: turn a growing collection of evaluations, trials and partnership discussions into paying customers. The Brisbane-based battery materials and life sciences company reported FY2026 sales revenue of A$460,397, slightly below the A$467,589 recorded in FY2025.
Total revenue fell from A$3.46 million to A$3.13 million. The company noted that FY2025 sales included an additional A$276,863 payment from the Serum Institute of India, while a further A$134,138 sale completed on 7 July 2026 will be recognised in FY2027 rather than in the year just ended.
Lower Costs Cushion a Still Loss-Making Business
AnteoTech reduced operating expenses to A$6.86 million in FY2026, excluding depreciation, amortisation and share-based payments, from A$8.45 million a year earlier and A$10.89 million in FY2024. The presentation’s loss chart shows a FY2026 loss of A$5.38 million, compared with A$6.76 million in FY2025.
Cash in the bank was A$11.2 million at 30 June 2026. The company also lists an R&D tax rebate claim among its corporate priorities for the new year, but the presentation does not quantify that claim or treat it as FY2027 sales.
Battery Products Move Through Validation
AnteoTech’s advanced battery technology portfolio spans high-silicon anode products Ultranode 70, Ultranode 95 and Ultranode X, alongside the Anteo X, Anteo S, Anteo C and SiMRAX additives. The FY2026 review highlights Ultranode 95 work at the Battery Innovation Center, Ultranode 70 evaluation in commercial cell format by Wyon, and discussions around drone anode joint development agreements.
The company also points to customer trials for SiMRAX, evaluations involving Anteo S and Anteo C, and a planned push into defence, unmanned aerial systems, eVTOL and consumer battery applications. These are development and commercialisation pathways rather than disclosed purchase orders, making conversion speed more important than the size of the markets cited in the presentation.
Life Sciences Expansion Relies on Customer Conversion
In life sciences, AnteoTech says its five-year US$1.8 million contract with the Serum Institute of India remains an existing sales channel, while an AnteoBind NXT activated ELISA plate prototype is under evaluation by the institute. The company is also pursuing CLIA and ELISA opportunities across India, the United States, Europe, Japan and South Korea.
FY2027 priorities include converting those evaluations into sales, progressing CLIA strategic partnerships, entering the ELISA market and expanding distributor and business-development channels. The next commercial evidence will need to come in the form of repeat orders, binding agreements or other revenue-bearing milestones rather than further sampling alone.
Bottom Line?
AnteoTech has bought itself more runway through lower costs and A$11.2 million of cash, but FY2027 will hinge on whether its evaluation pipeline becomes dependable revenue before that runway narrows.
Questions in the middle?
- How quickly can customer evaluations in battery and life sciences convert into repeat sales?
- Which of the Ultranode, Anteo S, Anteo C and SiMRAX opportunities will produce binding commercial agreements first?
- How much cash will AnteoTech consume while it pursues partnerships, validation programs and market entry?